[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637340":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":16,"studyPopulation":20,"armGroups":21,"interventions":31,"overallOfficials":37,"centralContacts":40,"locations":48,"responsibleParty":59,"collaborators":16,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":16,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":16,"enrollmentInfo":70,"targetDuration":16,"studyType":73,"phases":16,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":79,"whyStopped":16,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":16},[9],{"measure":10,"description":11,"timeFrame":12},"Number of participants experiencing adverse events","Adverse events include: adverse drug reaction (ADR), serious adverse event (SAE), serious adverse drug reaction (SADR), unexpected adverse event (AE), unexpected ADR, unexpected SAE or SADR and adverse events of special interest (AESI)","Up to 12 months",[14],{"measure":15,"description":16,"timeFrame":12},"Number of participants achieving objective tumor response according to RECIST version 1.1",null,{"allocation":16,"interventionModel":16,"interventionModelDescription":16,"primaryPurpose":16,"observationalModel":18,"timePerspective":19,"maskingInfo":16},"COHORT","PROSPECTIVE","Korean participants with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) or solid tumors harboring Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusions who are prescribed repotrectinib in routine clinical practice.",[22,27],{"label":23,"type":16,"description":24,"interventionNames":25},"ROS1-Positive NSCLC Cohort","Participants ≥19 years with histologically or cytologically confirmed locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)",[26],"Drug: Repotrectinib",{"label":28,"type":16,"description":29,"interventionNames":30},"NTRK Gene Fusion Solid Tumor Cohort","Participants ≥12 years with solid tumors harboring NTRK gene fusions that are locally advanced, metastatic, or likely to cause severe morbidity if surgically resected",[26],[32],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":16},"DRUG","Repotrectinib","As per product label",[28,23],[38],{"name":5,"affiliation":5,"role":39},"STUDY_DIRECTOR",[41,46],{"name":42,"role":43,"phone":44,"phoneExt":16,"email":45},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":47,"role":43,"phone":16,"phoneExt":16,"email":16},"First line of the email MUST contain NCT # and Site #.",[49],{"facility":50,"status":16,"city":51,"state":16,"zip":16,"country":52,"countryCode":16,"cosmosGeoPoint":53,"geoPoint":58,"contacts":16},"Bristol Myers Squibb Pharmaceutical Korea Ltd","Seoul","South Korea",{"type":54,"coordinates":55},"Point",[56,57],126.9784,37.566,{"lat":57,"lon":56},{"type":60,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR","100637340","repotrectinib-post-marketing-surveillance-in-korean-patients-with-ros1-positive-non-small-cell-lung-cancer-nsclc-or-solid-tumors-harboring-a-neurotrophic-tyrosine-receptor-kinase-ntrk-gene-fusion-100637340",false,"NCT07599007","Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion","AUGTYRO™ (Repotrectinib) Post-Marketing Surveillance in Korean Patients With Locally Advanced or Metastatic Ros1-Positive NSCLC or Solid Tumors Harboring a NTRK Gene Fusion","Inclusion Criteria:\n\n* Participants aged ≥19 years with histologically OR cytologically confirmed locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)\n* Participants aged ≥12 years with solid tumors harboring Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusions\n* Documented ROS1 or NTRK 1-3 gene fusion by validated local testing\n* Written informed consent\n\nExclusion Criteria:\n\n* Treatment with repotrectinib for indications not approved in Korea\n* Treatment with repotrectinib at dosages not approved in Korea\n* Contraindication to repotrectinib according to MFDS prescribing information","ALL","12 Years",{"count":71,"type":72},10,"ESTIMATED","OBSERVATIONAL","This observational study evaluates the real-world safety and effectiveness of repotrectinib in Korean participants with locally advanced or metastatic ROS1-positive non-small cell lung cancer or solid tumors harboring neurotrophic tyrosine receptor kinase (NTRK) gene fusions. Participants receiving repotrectinib in routine clinical practice will be followed for up to 12 months or until the end of the 2-year surveillance period, whichever occurs first.",[76],"Non-Small Cell Lung Cancer",[76,78],"NSCLC","NOT_YET_RECRUITING","2026-09-29",{"date":82,"type":83},"2026-09-30","ACTUAL",{"date":85,"type":72},"2026-10-31",{"date":87,"type":72},"2028-01-31",{"name":5,"class":6},1]